THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
NCT ID: NCT03354429
Last Updated: 2020-12-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
11016 participants
INTERVENTIONAL
2018-01-22
2019-12-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TICAGRELOR
Ticagrelor
Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
TICAGRELOR PLACEBO
Placebo
Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ticagrelor
Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
Placebo
Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. ≥40 years of age
3. Acute onset of cerebral ischaemia due to
1. AIS with NIHSS ≤5. AIS is defined as acute onset of neurological deficit attributed to focal brain ischaemia, and either of the following:
* Persistent signs or symptoms of the ischaemic event at the time o randomisation, OR
* Acute ischaemic brain lesion documented before randomisation by computed tomography (CT) scan or magnetic resonance imaging (MRI) (diffusion-weighted imaging) and that could account for the clinical presentation
2. High-risk TIA, defined as neurological deficit of acute onset attributed to focal ischaemia of the brain by history or examination with complete resolution of the deficit, and at least one of the following:
* ABCD2 score ≥6 and TIA symptoms not limited to isolated numbness, isolated visual changes, or isolated dizziness/vertigo
* Symptomatic intracranial arterial occlusive disease that could account for the clinical presentation, documented by transcranial Doppler or vascular imaging and defined as at least 50% narrowing in the diameter of the vessel lumen
* Internal carotid arterial occlusive disease that could account for the clinical presentation, documented by Doppler, ultrasound, or vascular imaging and defined as at least 50% narrowing in diameter of the vessel lumen
4. Randomisation occurring within 24 hours after onset of symptoms; for wake-up strokes (when the time of symptom onset is not known), within 24 hours from the time point at which the patient was reported to be in their normal condition
5. CT or MRI performed after symptom onset ruling out intracranial haemorrhage or other pathology, such as vascular malformation, tumour, or abscess that according
to the Investigator could explain symptoms or contraindicate study treatment
Exclusion Criteria
1. Dual antiplatelet therapy with ASA and P2Y12 inhibitors (including patients with carotid artery stenting and percutaneous coronary intervention)
2. Antiplatelets other than ASA (eg, GPIIb/IIIa inhibitors, clopidogrel, ticlopidine, prasugrel, dipyridamole, ozagrel, cilostazol, ticagrelor) and other antithrombotic agents with antiplatelet effects, including traditional/herbal medicine agents
3. Anticoagulants (eg, warfarin, oral thrombin and factor Xa inhibitors, bivalirudin, hirudin, argatroban, fondaparinux, or unfractionated heparin and long-term treatment with low-molecular weight heparins). Short-term treatment (≤7 days) with low-dose low-molecular weight heparin may be used in immobilised patients at the discretion of the Investigator
2. Any history of atrial fibrillation/flutter, ventricular aneurysm, or suspicion of other cardioembolic pathology for TIA or stroke
3. Patients who should receive or have received any intravenous or intra-arterial thrombolysis or mechanical thrombectomy within 24 hours prior to randomisation
4. Planned carotid endarterectomy that requires halting investigational product within 3 days of randomisation or is expected to require unblinding of investigational product (planned carotid endarterectomy is in itself not an exclusion criterion)
5. History of previous intracranial haemorrhage at any time (asymptomatic microbleeds do not qualify), gastrointestinal haemorrhage within the past 6 months, or major surgery within 30 days
6. Patients considered to be at risk of bradycardic events (eg, known sick sinus syndrome or second- or third-degree atrioventricular block) unless already treated with a permanent pacemaker
7. Inability of the patient to understand and/or comply with study procedures and/or follow-up, in the opinion of the Investigator
8. Known hypersensitivity to ticagrelor or ASA
9. Need for or an anticipated need for oral or intravenous therapy with any of the following:
1. Strong cytochrome P450 3A (CYP3A4) inhibitors (eg, ketoconazole, clarithromycin \[but not erythromycin or azithromycin\], nefazadone, ritonavir, atazanavir) that cannot be stopped for the course of the study
2. Long-term (\>7 days) non-steroidal anti-inflammatory drugs
10. Known bleeding diathesis or coagulation disorder (eg, thrombotic thrombocytopenic purpura)
11. Known severe liver disease (eg, ascites or signs of coagulopathy)
12. Renal failure requiring dialysis
13. Pregnancy or breastfeeding. Women of child-bearing potential who are not willing to use a medically accepted method of contraception that is considered reliable in the judgment of the Investigator
14. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
15. Previous enrolment or randomisation in the present study
16. Participation in another clinical study with an investigational product at any time during the 30 days prior to randomisation (regardless of when treatment with the investigational product was discontinued)
40 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Adrogué, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
Capital Federal, , Argentina
Research Site
Ciudad Autónoma de Bs. As., , Argentina
Research Site
Córdoba, , Argentina
Research Site
Mar del Plata, , Argentina
Research Site
Mendoza, , Argentina
Research Site
Rosario, , Argentina
Research Site
Rosario, , Argentina
Research Site
Salta, , Argentina
Research Site
Adelaide, , Australia
Research Site
Heidelberg, , Australia
Research Site
Herston, , Australia
Research Site
Parkville, , Australia
Research Site
Southport, , Australia
Research Site
St Albans, , Australia
Research Site
Antwerp, , Belgium
Research Site
Assebroek (Brugge), , Belgium
Research Site
Bruges, , Belgium
Research Site
Brussels, , Belgium
Research Site
Dendermonde, , Belgium
Research Site
Edegem, , Belgium
Research Site
Kortrijk, , Belgium
Research Site
Leuven, , Belgium
Research Site
Liège, , Belgium
Research Site
Ostend, , Belgium
Research Site
Roeselare, , Belgium
Research Site
Sint-Truiden, , Belgium
Research Site
Yvoir, , Belgium
Research Site
Botucatu, , Brazil
Research Site
Curitiba, , Brazil
Research Site
Goiânia, , Brazil
Research Site
Joinville, , Brazil
Research Site
Maringá, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Ribeirão Preto, , Brazil
Research Site
Rio de Janeiro, , Brazil
Research Site
Salvador, , Brazil
Research Site
Dupnitsa, , Bulgaria
Research Site
Kozloduy, , Bulgaria
Research Site
Lukovit, , Bulgaria
Research Site
Pazardzhik, , Bulgaria
Research Site
Pleven, , Bulgaria
Research Site
Sliven, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Teteven, , Bulgaria
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Lethbridge, Alberta, Canada
Research Site
Chicoutimi, , Canada
Research Site
Baoji, , China
Research Site
Baotou, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Changsha, , China
Research Site
Changsha, , China
Research Site
Changsha, , China
Research Site
Chifeng, , China
Research Site
Daqing, , China
Research Site
Foshan, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Guiyang, , China
Research Site
Haikou, , China
Research Site
Hangzhou, , China
Research Site
Hohhot, , China
Research Site
Hohhot, , China
Research Site
Jinan, , China
Research Site
Jinzhou, , China
Research Site
Liuzhou, , China
Research Site
Nanchang, , China
Research Site
Nanjing, , China
Research Site
Nantong, , China
Research Site
Ningbo, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shenyang, , China
Research Site
Taiyuan, , China
Research Site
Tangshan, , China
Research Site
Tianjin, , China
Research Site
Tianjin, , China
Research Site
Wenzhou, , China
Research Site
Wuhan, , China
Research Site
Wuhan, , China
Research Site
Wuhan, , China
Research Site
Wuxi, , China
Research Site
Xi'an, , China
Research Site
Xiamen, , China
Research Site
Xining, , China
Research Site
Xuzhou, , China
Research Site
Brno, , Czechia
Research Site
Chomutov, , Czechia
Research Site
Ostrava, , Czechia
Research Site
Ostrava, , Czechia
Research Site
Pardubice, , Czechia
Research Site
Prague, , Czechia
Research Site
Ústí nad Labem, , Czechia
Research Site
Bayonne, , France
Research Site
Besançon, , France
Research Site
Bordeaux, , France
Research Site
Bourg-en-Bresse, , France
Research Site
Brest, , France
Research Site
Caen, , France
Research Site
Corbeil-Essonnes, , France
Research Site
Dijon, , France
Research Site
Le Chesnay, , France
Research Site
Lille, , France
Research Site
Metz, , France
Research Site
Montpellier, , France
Research Site
Nancy, , France
Research Site
Nice, , France
Research Site
Paris, , France
Research Site
Paris, , France
Research Site
Paris, , France
Research Site
Paris, , France
Research Site
Paris, , France
Research Site
Rennes, , France
Research Site
Rouen, , France
Research Site
Saint-Herblain, , France
Research Site
Saint-Priez En Jarez, , France
Research Site
Strasbourg, , France
Research Site
Suresnes, , France
Research Site
Toulouse, , France
Research Site
Altenburg, , Germany
Research Site
Bad Neustadt an der Saale, , Germany
Research Site
Berlin, , Germany
Research Site
Erlangen, , Germany
Research Site
Essen, , Germany
Research Site
Hamburg, , Germany
Research Site
Hamburg, , Germany
Research Site
Hamburg, , Germany
Research Site
Hamburg, , Germany
Research Site
Hanover, , Germany
Research Site
Minden, , Germany
Research Site
Münster, , Germany
Research Site
Hong Kong, , Hong Kong
Research Site
Kowloon, , Hong Kong
Research Site
Baja, , Hungary
Research Site
Balassagyarmat, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Győr, , Hungary
Research Site
Kistarcsa, , Hungary
Research Site
Miskolc, , Hungary
Research Site
Nyíregyháza, , Hungary
Research Site
Pécs, , Hungary
Research Site
Sopron-Balf, , Hungary
Research Site
Székesfehérvár, , Hungary
Research Site
Tatabánya, , Hungary
Research Site
Bangalore, , India
Research Site
Bangalore, , India
Research Site
Bengaluru, , India
Research Site
Dehradun, , India
Research Site
Guntur, , India
Research Site
Gurgaon, , India
Research Site
Gurgaon, , India
Research Site
Hyderabad, , India
Research Site
Kanpur, , India
Research Site
Kolkata, , India
Research Site
Mangalore, , India
Research Site
Nagpur, , India
Research Site
Nagpur, , India
Research Site
Nashik, , India
Research Site
New Delhi, , India
Research Site
New Delhi, , India
Research Site
New Delhi, , India
Research Site
Srikakulam, , India
Research Site
Varanasi, , India
Research Site
Cona, , Italy
Research Site
Genova, , Italy
Research Site
Genova, , Italy
Research Site
Massa, , Italy
Research Site
Milan, , Italy
Research Site
Modena, , Italy
Research Site
Negrar, , Italy
Research Site
Pavia, , Italy
Research Site
Perugia, , Italy
Research Site
Pietra Ligure, , Italy
Research Site
Pisa, , Italy
Research Site
Roma, , Italy
Research Site
Roma, , Italy
Research Site
Roma, , Italy
Research Site
Siena, , Italy
Research Site
Varese, , Italy
Research Site
Verona, , Italy
Research Site
Vicenza, , Italy
Research Site
Vizzolo Predabissi, , Italy
Research Site
Culiacán, , Mexico
Research Site
D.F, , Mexico
Research Site
Durango, , Mexico
Research Site
Guadalajara, , Mexico
Research Site
Mexico City, , Mexico
Research Site
Mexico City, , Mexico
Research Site
México, , Mexico
Research Site
México, , Mexico
Research Site
Monterrey, , Mexico
Research Site
Tijuana, , Mexico
Research Site
Bellavista, , Peru
Research Site
Callao, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Trujillo, , Peru
Research Site
Urb. El Chipe, , Peru
Research Site
Bialystok, , Poland
Research Site
Chełm, , Poland
Research Site
Działdowo, , Poland
Research Site
Gdansk, , Poland
Research Site
Gdansk, , Poland
Research Site
Gmina Końskie, , Poland
Research Site
Gmina Świebodzin, , Poland
Research Site
Grodzisk Mazowiecki, , Poland
Research Site
Gryfice, , Poland
Research Site
Katowice, , Poland
Research Site
Krakow, , Poland
Research Site
Lodz, , Poland
Research Site
Lodz, , Poland
Research Site
Lublin, , Poland
Research Site
Olsztyn, , Poland
Research Site
Olsztyn, , Poland
Research Site
Ostrołęka, , Poland
Research Site
Rybnik, , Poland
Research Site
Sandomierz, , Poland
Research Site
Skarżysko-Kamienna, , Poland
Research Site
Warsaw, , Poland
Research Site
Warsaw, , Poland
Research Site
Zielona Góra, , Poland
Research Site
Bucharest, , Romania
Research Site
Bucharest, , Romania
Research Site
Bucharest, , Romania
Research Site
Iași, , Romania
Research Site
Oradea, , Romania
Research Site
Sibiu, , Romania
Research Site
Târgu Mureş, , Romania
Research Site
Timișoara, , Romania
Research Site
Chelyabinsk, , Russia
Research Site
Izhevsk, , Russia
Research Site
Kazan', , Russia
Research Site
Kazan', , Russia
Research Site
Kemerovo, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Nizhny Novgorod, , Russia
Research Site
Nizhny Novgorod, , Russia
Research Site
Novosibirsk, , Russia
Research Site
Novosibirsk, , Russia
Research Site
Ryazan, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Samara, , Russia
Research Site
Samara, , Russia
Research Site
Saratov, , Russia
Research Site
Sochi, , Russia
Research Site
Tomsk, , Russia
Research Site
Ufa, , Russia
Research Site
Voronezh, , Russia
Research Site
Yaroslavl, , Russia
Research Site
Yekaterinburg, , Russia
Research Site
Jeddah, , Saudi Arabia
Research Site
Riyadh, , Saudi Arabia
Research Site
Riyadh, , Saudi Arabia
Research Site
Riyadh, , Saudi Arabia
Research Site
Dolný Kubín, , Slovakia
Research Site
Levoča, , Slovakia
Research Site
Liptovský Mikuláš, , Slovakia
Research Site
Martin, , Slovakia
Research Site
Nitra, , Slovakia
Research Site
Rimavská Sobota, , Slovakia
Research Site
Skalica, , Slovakia
Research Site
Spišská Nová Ves, , Slovakia
Research Site
Trenčín, , Slovakia
Research Site
Trnava, , Slovakia
Research Site
Žiar nad Hronom, , Slovakia
Research Site
Anyang-si, , South Korea
Research Site
Busan, , South Korea
Research Site
Busan, , South Korea
Research Site
Cheongju-si, , South Korea
Research Site
Daegu, , South Korea
Research Site
Daegu, , South Korea
Research Site
Daegu, , South Korea
Research Site
Daejeon, , South Korea
Research Site
Goyang-si, , South Korea
Research Site
Gwangju, , South Korea
Research Site
Incheon, , South Korea
Research Site
Jeju-do, , South Korea
Research Site
Seongnam-si, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Albacete, , Spain
Research Site
Alicante, , Spain
Research Site
Badalona(Barcelona), , Spain
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Girona, , Spain
Research Site
Lleida, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Seville, , Spain
Research Site
Seville, , Spain
Research Site
Valencia, , Spain
Research Site
Valladolid, , Spain
Research Site
Zaragoza, , Spain
Research Site
Gothenburg, , Sweden
Research Site
Linköping, , Sweden
Research Site
Lund, , Sweden
Research Site
Malmo, , Sweden
Research Site
Östersund, , Sweden
Research Site
Skövde, , Sweden
Research Site
Solna, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Uppsala, , Sweden
Research Site
Changhua, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Keelung, , Taiwan
Research Site
New Taipei City, , Taiwan
Research Site
New Taipei City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Tainan City, , Taiwan
Research Site
Tainan City, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan Hsien, , Taiwan
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Chon Buri, , Thailand
Research Site
Hat Yai, , Thailand
Research Site
Khlong Luang, , Thailand
Research Site
Khon Kaen, , Thailand
Research Site
Lampang, , Thailand
Research Site
Muang, , Thailand
Research Site
Nakhonpathom, , Thailand
Research Site
Prachinburi, , Thailand
Research Site
Rajthevi, , Thailand
Research Site
Ratchaburi, , Thailand
Research Site
Ubonratchathani, , Thailand
Research Site
Chernivtsі, , Ukraine
Research Site
Ivano-Frankivsk, , Ukraine
Research Site
Ivano-Frankivsk, , Ukraine
Research Site
Kharkiv Region, , Ukraine
Research Site
Kharkiv Region, , Ukraine
Research Site
Kherson, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Lutsk, , Ukraine
Research Site
Lviv, , Ukraine
Research Site
Poltava, , Ukraine
Research Site
Ternopil, , Ukraine
Research Site
Vinnytsia, , Ukraine
Research Site
Zaporizhzhia, , Ukraine
Research Site
Zaporizhzhia, , Ukraine
Research Site
Hanoi, , Vietnam
Research Site
Hà Nội, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Research Site
Đông Nãi, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tank A, Johnston SC, Jain R, Amarenco P, Mellstrom C, Rikner K, Denison H, Ladenvall P, Knutsson M, Himmelmann A, Evans SR, James S, Molina CA, Wang Y, Ouwens M. Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial. BMJ Neurol Open. 2023 Aug 24;5(2):e000478. doi: 10.1136/bmjno-2023-000478. eCollection 2023.
Johnston SC, Amarenco P, Aunes M, Denison H, Evans SR, Himmelmann A, Jahreskog M, James S, Knutsson M, Ladenvall P, Molina CA, Nylander S, Rother J, Wang Y; THALES Investigators. Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Stroke. 2021 Nov;52(11):3482-3489. doi: 10.1161/STROKEAHA.121.035555. Epub 2021 Sep 3.
Wang Y, Pan Y, Li H, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Birve F, Ladenvall P, Molina CA, Johnston SC; THALES Steering Committee and Investigators. Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial. JAMA Neurol. 2021 Sep 1;78(9):1091-1098. doi: 10.1001/jamaneurol.2021.2440.
Yaghi S, de Havenon A, Rostanski S, Kvernland A, Mac Grory B, Furie KL, Kim AS, Easton JD, Johnston SC, Henninger N. Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial. Stroke. 2021 Jul;52(7):2414-2417. doi: 10.1161/STROKEAHA.121.034089. Epub 2021 May 4.
Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Johnston SC; THALES Steering Committee and Investigators*. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke. 2020 Dec;51(12):3504-3513. doi: 10.1161/STROKEAHA.120.032239. Epub 2020 Nov 16.
Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Johnston SC; THALES Steering Committee and Investigators. Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial. JAMA Neurol. 2020 Nov 7;78(2):1-9. doi: 10.1001/jamaneurol.2020.4396. Online ahead of print.
Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y; THALES Investigators. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med. 2020 Jul 16;383(3):207-217. doi: 10.1056/NEJMoa1916870.
Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y; THALES Investigators. The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design. Int J Stroke. 2019 Oct;14(7):745-751. doi: 10.1177/1747493019830307. Epub 2019 Feb 12.
Wong KSL, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Himmelmann A, Kasner SE, Knutsson M, Ladenvall P, Minematsu K, Molina CA, Wang Y, Johnston SC; SOCRATES Steering Committee and Investigators. Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial. Stroke. 2018 Jul;49(7):1678-1685. doi: 10.1161/STROKEAHA.118.020553. Epub 2018 Jun 18.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Document Type: Study Protocol
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-004232-37
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D5134C00003
Identifier Type: -
Identifier Source: org_study_id